Number of the records: 1  

Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects

  1. 1.
    SYSNO ASEP0108994
    Document TypeJ - Journal Article
    R&D Document TypeJournal Article
    Subsidiary JOstatní články
    TitleImmunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects
    TitleImunogenicita HPV16 E6/E7 peptidových vakcín odvozených z dendritických buněk: aktivace a obranný účinek CTL
    Author(s) Indrová, Marie (UMG-J) RID
    Reiniš, Milan (UMG-J) RID
    Bubeník, Jan (UMG-J)
    Jandlová, Táňa (UMG-J)
    Bieblová, Jana (UMG-J)
    Vonka, V. (CZ)
    Velek, Jiří (UOCHB-X)
    Source TitleFolia Biologica. - : Univerzita Karlova v Praze - ISSN 0015-5500
    Roč. 50, č. 6 (2004), s. 184-193
    Number of pages10 s.
    Languageeng - English
    CountryCZ - Czech Republic
    KeywordsHPV16 E6/E7 peptides ; dendritic cells ; cytotoxic lymphocytes
    Subject RIVEC - Immunology
    R&D ProjectsNC7148 GA MZd - Ministry of Health (MZ)
    NR7807 GA MZd - Ministry of Health (MZ)
    GA301/01/0985 GA ČR - Czech Science Foundation (CSF)
    GA301/04/0492 GA ČR - Czech Science Foundation (CSF)
    KSK5011112 GA AV ČR - Academy of Sciences of the Czech Republic (AV ČR)
    CEZAV0Z5052915 - UMG-J
    AnnotationWe have investigated the capacity of cellular vaccines based on dendritic cells loaded with human HPV16 E6/E7 oncoprotein-derived peptides to induce immune responses in vitro and to elicit protective immunity in a murine experimental model mimicking human HPV16-associated carcinomas. We have found a good correlation between the vaccine efficacy in vitro, determined by chromium release cytotoxic tests, and the level of protection against tumour growth in immunization-challenge experiments. The results from both in vitro and in vivo experiments revealed that BMDC-based cellular vaccines pulsed with peptides, which exceed the length optimal for binding of the MHC class I and which harbour the Th epitope, are capable to elicit strong and protective CTL-based immunity against HPV16-associated MHC class I positive tumours
    WorkplaceInstitute of Molecular Genetics
    ContactNikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217
    Year of Publishing2005

Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.